SELLAS Life Sciences Group, Inc. (SLS) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $0.00 |
| Revenue (TTM) | $0.0B |
| Return on Equity | -24.4% |
| Operating Margin (TTM) | -4195.0% |
| Current Ratio | 18.83 |
| Revenue Growth (YoY) | -100.0% |
| Revenue Growth (3Y) | -100.0% |
| EPS Growth (YoY) | -37.1% |
| Price / Book | 15.60 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
SLS overview · SLS earnings · SLS KPIs · SLS documents · SLS ownership · SLS peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.